These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 22892365)

  • 1. The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series.
    Peterson K; Ruelle J; Vekemans M; Siegal FP; Deayton JR; Colebunders R
    Antivir Ther; 2012; 17(6):1097-100. PubMed ID: 22892365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART.
    Nicastri E; Tommasi C; Abbate I; Bonora S; Tempestilli M; Bellagamba R; Viscione M; Rozera G; Gallo AL; Ivanovic J; Amendola A; Pucillo L; Di Perri G; Capobianchi MR; Narciso P
    Antivir Ther; 2011; 16(6):797-803. PubMed ID: 21900711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient.
    Wandeler G; Furrer H; Rauch A
    AIDS; 2011 Nov; 25(18):2306-8. PubMed ID: 22067200
    [No Abstract]   [Full Text] [Related]  

  • 4. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
    Cordery DV; Hesse K; Amin J; Cooper DA
    Antivir Ther; 2010; 15(7):1035-8. PubMed ID: 21041919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
    Llibre JM; Buzón MJ; Massanella M; Esteve A; Dahl V; Puertas MC; Domingo P; Gatell JM; Larrouse M; Gutierrez M; Palmer S; Stevenson M; Blanco J; Martinez-Picado J; Clotet B
    Antivir Ther; 2012; 17(2):355-64. PubMed ID: 22290239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
    Adjé-Touré CA; Cheingsong R; Garcìa-Lerma JG; Eholié S; Borget MY; Bouchez JM; Otten RA; Maurice C; Sassan-Morokro M; Ekpini RE; Nolan M; Chorba T; Heneine W; Nkengasong JN
    AIDS; 2003 Jul; 17 Suppl 3():S49-54. PubMed ID: 14565609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance.
    Mangiafico L; Perja M; Fusco F; Riva S; Mago D; Gringeri A
    Haemophilia; 2012 Jan; 18(1):108-11. PubMed ID: 21762404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients.
    Caby F; Valin N; Marcelin AG; Schneider L; Andrade R; Guiguet M; Tubiana R; Canestri A; Valantin MA; Peytavin G; Pacanowski J; Morand-Joubert L; Calvez V; Girard PM; Katlama C
    Scand J Infect Dis; 2010 Jul; 42(6-7):527-32. PubMed ID: 20222846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.
    Armstrong-James D; Stebbing J; Scourfield A; Smit E; Ferns B; Pillay D; Nelson M
    Antiviral Res; 2010 May; 86(2):224-6. PubMed ID: 20211653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient increment of HTLV-2 proviral load in HIV-1-co-infected patients during treatment intensification with raltegravir.
    Abad-Fernández M; Cabrera C; García E; Vallejo A
    J Clin Virol; 2014 Mar; 59(3):204-7. PubMed ID: 24457115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir.
    Garrido C; Rallón N; Soriano V; Lopez M; Zahonero N; de Mendoza C; Benito JM
    AIDS; 2012 Mar; 26(5):551-7. PubMed ID: 22210634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raltegravir: the first HIV type 1 integrase inhibitor.
    Hicks C; Gulick RM
    Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunologic effectiveness of maraviroc- and raltegravir-containing regimens (R+M+) versus raltegravir-based regimens that do not include maraviroc (R+M-).
    Antoniou T; Smith G; Su D; Raboud JM; Lee D; Kovacs C; Brunetta J; Fletcher D; Crouzat F; Loutfy M
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(3):192-7. PubMed ID: 22247337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
    Canducci F; Barda B; Ceresola E; Spagnuolo V; Sampaolo M; Boeri E; Nozza S; Cossarin F; Galli A; Gianotti N; Castagna A; Lazzarin A; Clementi M
    Clin Microbiol Infect; 2011 Jun; 17(6):928-34. PubMed ID: 20854427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
    AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
    Cooper DA; Steigbigel RT; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Teppler H; Nguyen BY;
    N Engl J Med; 2008 Jul; 359(4):355-65. PubMed ID: 18650513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of raltegravir in HIV-1 management.
    Rokas KE; Bookstaver PB; Shamroe CL; Sutton SS; Millisor VE; Bryant JE; Weissman SB
    Ann Pharmacother; 2012 Apr; 46(4):578-89. PubMed ID: 22496475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells.
    Reigadas S; Andréola ML; Wittkop L; Cosnefroy O; Anies G; Recordon-Pinson P; Thiébaut R; Masquelier B; Fleury H
    J Antimicrob Chemother; 2010 Mar; 65(3):434-7. PubMed ID: 20051476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.